Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEMIA Pilot Study
PACTR202412922137727Not yet recruiting
- Sponsor
- National Institutes of Health
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cabotegravir, dapivirine and emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institutes of Health. Primary endpoints: PrEP uptake and 3-month PrEP persistence. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
cabotegravirdapivirineemtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202412922137727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202412922137727.